Document Detail

Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice.
MedLine Citation:
PMID:  10750653     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To identify health outcomes and costs/savings of a Helicobacter pylori test-and-treat strategy in patients using acid suppressants chronically. DESIGN: Prospective intervention study. Patients were tested for H. pylori infection and treated with 14 days of ranitidine bismuth citrate (RBC) 400 mg (b.i.d.) and clarithromycin 500 mg if infected. Cure was determined after six months. SETTING: General practice. PARTICIPANTS: Patients using acid suppressants chronically were identified by a computer search; 184 patients gave written consent and were included. MAIN OUTCOME MEASURES: Serology, symptom questionnaire, medication history, quality of life determination, costs/savings. RESULTS: Out of 184 patients, 85 (46%) had positive serology. A cure rate of 61/80 (76%) was achieved. The intervention group showed significant symptom relief. Benefits were evident in patients with ulcer disease but also in patients with uninvestigated dyspepsia. Quality of life improved for cured patients in the intervention group. No improvements for dyspeptic symptoms or quality of life occurred in the H. pylori-negative group. After six months, significant savings for medication use had occurred in treated patients diagnosed as ulcer disease or non-ulcer dyspepsia. Savings on drug use and doctor visits equalize with costs for tests and antibiotics after nine months. Although less, costs for drugs also decreased significantly in the H. pylori-negative group. Therefore, for the study population, costs and savings are even after 6.5 months. CONCLUSIONS: A test-and-treat strategy for H. pylori, systematically applied at the population level in patients using acid suppressants chronically, results in significant health benefits and economic savings within 1 year of follow-up.
E A Joosen; J H Reininga; J M Manders; J C ten Ham; W A de Boer
Related Documents :
8730253 - Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple...
10793333 - Opportunistic actinomycosis in osteoradionecrosis of the jaws in patients affected by h...
1636873 - The efficacy of halofantrine in the treatment of acute malaria in nonimmune travelers.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  12     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-05-16     Completed Date:  2000-05-16     Revised Date:  2009-10-16    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  319-25     Citation Subset:  IM    
Clinical/Epidemiological Research, Delft, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / economics,  therapeutic use*
Clarithromycin / economics,  therapeutic use*
Cost Savings
Costs and Cost Analysis
Drug Therapy, Combination
Family Practice
Helicobacter Infections / drug therapy*,  economics*,  microbiology
Helicobacter pylori / isolation & purification*
Histamine H2 Antagonists / economics,  therapeutic use*
Middle Aged
Prospective Studies
Quality of Life
Ranitidine / economics,  therapeutic use*
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Histamine H2 Antagonists; 66357-35-5/Ranitidine; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, ...
Next Document:  A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern ...